The VPM1002 vaccine, which was developed at the Max Planck Institute for Infection Biology, is based on the BCG vaccine and contains genetically modified Mycobacterium bovis bacteria. A built-in gene makes it easier for the immune cells to recognize the bacteria; the organism can thus protect it...
We aimed to compare safety and immunogenicity of VPM1002—a recombinant BCG vaccine developed to address this gap—with BCG in HIV exposed and HIV unexposed newborn babies. Methods This double-blind, randomised, active controlled phase 2 study was conducted at four health centres in South Africa...
The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines. 2014; 13: 619-630.Kaufmann SH, Cotton MF, Eisele B, Gengenbacher M, Grode L, Hes- seling AC, Walzl G. 2014. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. ...
2014. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines 13:619 - 630. http:// dx.doi.org/10.1586/14760584.2014.905746.Kaufmann SH, Cotton MF, Eisele B, et al. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert ...
Newer candidates, such as VPM1002 Δpdx1 (PDX) and VPM1002 ΔnuoG (NUOG), were generated to further improve the safety profile or efficacy of the vaccine. Herein, we assessed the safety and immunogenicity of VPM1002 and its derivatives, PDX and NUOG, in juvenile goats. Vaccination did ...